STOCKS TELEGRAPH

Tag: STRO STOCK

  • After-Market Gains For Sutro Biopharma (STRO) Following An Investor Webcast

    After-Market Gains For Sutro Biopharma (STRO) Following An Investor Webcast

    Shares of Sutro Biopharma, Inc. (NASDAQ: STRO) demonstrated a notable recovery in the wake of an investor webcast, rebounding by 2.72% in after-hours trading to reach $3.40, despite experiencing a regular session decline of 4.34%, concluding at $3.31. This upward movement reflects growing investor interest following the company’s recent announcements.

    Highlights of the Investor Webcast

    During the webcast held on Thursday, Sutro Biopharma showcased its proprietary cell-free platform and its role in the design and development of next-generation antibody-drug conjugates (ADCs). The presentation emphasized a near-term pipeline of differentiated programs with promising potential across various tumor types.

    Sutro’s strategic approach aims to enhance the therapeutic index of ADCs, presenting details on its early-stage ADC pipeline, including STRO-004, a tissue factor-targeting ADC, dual-payload ADCs (ADC2), and immunostimulatory ADCs (iADC).

    Advancements in ADC Design

    Sutro’s innovative cell-free platform has empowered the development of ADCs with unique features not achievable through traditional cell-bound methodologies. This advanced design facilitates the safe enhancement of potency and the combination of different payloads to address specific challenges, such as tumor resistance.

    The company highlighted pivotal data demonstrating its progress in these areas and underscored the long-term potential of its platform to pioneer new ADC innovations. Sutro is also planning to file Investigational New Drug (IND) applications for three wholly owned programs over the next three years.

    Future Development and Collaboration

    The event featured insights from Sutro’s senior management team, including a presentation by Peter Sandor, M.D., EVP and Head of Corporate Strategy at Astellas Pharma. A Q&A session followed, allowing for further interaction with the management team.

    Sutro’s proprietary platform is designed to mitigate toxicities associated with current-generation ADCs, such as interstitial lung disease and various organ toxicities. The technology aims to enhance the design of antibodies, payloads, linkers, and conjugation chemistry, significantly improving pharmacokinetics and reducing adverse effects.

    Sutro Biopharma’s robust pipeline and innovative approaches signify promising opportunities in the ADC landscape, with plans to advance multiple preclinical programs for internal development or strategic partnerships.

  • Sutro Biopharma Inc. (STRO) stock Gains Further Pre-Market on Exclusive License Agreement

    Sutro Biopharma Inc. (STRO) stock Gains Further Pre-Market on Exclusive License Agreement

    Sutro Biopharma Inc. (STRO) advanced by a further 6.38% in the pre-market while it gained 2.25% during regular trading. On December 27, the company announced an exclusive license agreement for STRO-002 with Tasly Biopharmaceuticals. Hence, the news caused the stock to continue on a bullish path in the pre-market.

    During the regular session, the stock traded between $14.33 and $15.27, to close at $14.57. Currently, the 46.27 million outstanding shares of the company trade at a market capitalization of $659.35 million.

    STRO’s License Agreement with Tasly

    As per Monday’s announcement, the company entered into an exclusive license agreement with Tasly for developing and commercializing STRO-002. Further, the license encompasses Greater China including mainland China, Hong Kong, Macau, and Taiwan. Moreover, Tasly Biopharmaceuticals Co., Ltd. is a holding subsidiary of Tasly Pharmaceuticals Group Co., Ltd.

    STRO-002 is currently under study in the U.S. and Europe in ovarian and endometrial cancer patients.

    According to the agreement, $40 million will be paid to Sutro as an upfront payment. Moreover, Sutro will also be entitled to receive a further $345 million in commercial and milestones payments. The company will also be entitled to tiered, double-digit royalties on annual net sales of STRO-002 in the region. Furthermore, Tasly will develop and commercialize STRO-002 for ovarian and endometrial cancer with the future potential of expansion to include NSCLC (non-small cell lung cancer) and TNBC (triple-negative breast cancer.

    In addition, outside of Greater China STRO will be responsible for the development and commercialization of STRO-002.

    Recent Announcement

    The company further announced on Monday, that it will provide its interim data from the ongoing Phase 1 study of STRO-002 at a KOL virtual event. Further, the KOL event will be held o Wednesday, January 5, 2022.

    STRO’s Financial Analysis

    On November 10, the company disclosed its financial results for the third quarter of 2021, which ended on September 30, 2021.

    In the third quarter of 2021, STRO had revenue of $8.5 million, against$17.8 million in the year-ago quarter.

    Furthermore, the company incurred total operating expenses of $43.2 million in Q3 of 2020. This compares to $28.4 million in the third quarter of 2020.

    In addition, the company ended the third quarter of 2021, with cash, cash equivalents, and marketable securities of $254.2 million. Further, the company expects a cash runway into the second half of 2023.